Breast Cancer
Cape+BKM120 TNBC BC Brain met
Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Triple Negative Breast Cancer (TNBC) Patients with Brain Metastases

Ruxolitinib/placeb+Cape met Her2- Breast
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer (INCB 18424-268)

SystHERs HER2+ Breast Observational
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer

Palbociclib Post AI HR+HER2- MBC
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Fulvestrant (Faslodex®) with or without PD-0332991 Palbociclib/ Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

BMN673 vs PhyChoice gBRCA met Br
A Phase III, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease

MONALEESA2 LEE011+Lete Postmen HR+HER2-
A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease

Niraparib vs PhyChoice HER2-gBRCA Breast
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician’s Choice in Previously-Treated, HER2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Gynecologic Cancer
Trabectedin +/- PLD Adv Ovarian 2/3 In
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Leukemia
CML Observational Trial - SIMPLICITY
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

Lung Cancer
Nivolumab for Sqm or Non-Sqm NSCLC
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CA209153)

Docetaxel +/- Ganetespib NSCLC
A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma

LDK378 v SOC ALK+ NSCLC Post Chemo/Criz
A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Prostate Cancer
XL184 +Abiraterone w Bone Mets in cRPC
A Randomized Phase II Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naive Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer

Hematologic & Solid Tumors
PI3K Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-Activated Tumors

FGFR Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFRI, Trk and RET

Signature Series: RAS/RAF/MEK tumors
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK activated tumors

For more information or to refer a patient, call 855-234-HEAL.